Targeted drug therapy for kidney cancer

Targeted treatment of renal cancer The treatment of metastatic renal cancer has always been a major problem for patients and doctors. In recent years, with the continuous deepening of oncology research and the improvement of molecular biology technology, people have gained a better understanding of the pathogenesis of renal cancer and the biological characteristics of various renal cancer subtypes from the aspects of genetics, pathology and molecular biology.

Previous clinical trials have confirmed that several molecular targeted therapeutic drugs targeting vascular endothelial growth factor (VEGF) and mTOR have achieved good clinical results in the treatment of metastatic renal cancer. This result indicates that the treatment of metastatic renal cancer has entered the era of molecular targeted therapy.

Skin toxicity in targeted therapy for renal cancer The most common adverse reaction of molecular targeted drugs for VEGF is skin toxicity, including hand-foot skin reaction (HFSR) and rash. HFSR usually occurs in the early stage of treatment, and is usually most severe 2 weeks after medication. It will gradually subside thereafter. The pain will generally be significantly reduced or even disappear in the 6th to 7th week of treatment. As the treatment time increases, the incidence of HFSR also decreases.